A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics

Zhang,Chi; Ma,Qunfeng; Shi,Yinan; Li,Xue; Wang,Ming; Wang,Junfeng; Ge,Jianlin; Chen,Zhinan; Wang,Ziling; Jiang,Hong

doi:10.3892/or.2017.5539

A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics

Authors:
- Chi Zhang
- Qunfeng Ma
- Yinan Shi
- Xue Li
- Ming Wang
- Junfeng Wang
- Jianlin Ge
- Zhinan Chen
- Ziling Wang
- Hong Jiang
View Affiliations

Affiliations: College of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Haidian, Beijing 100044, P.R. China, Department of Thoracic Surgery, Affiliated Hospital of the Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China, Cell Engineering Research Center, The Fourth Military Medical University, Xicheng, Xi'an, Shaanxi 710032, P.R. China
Published online on: March 31, 2017 https://doi.org/10.3892/or.2017.5539
Pages: 2942-2954

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy. To further explore the resistance mechanism of 5-FU in ESCC, we established the 5-FU-resistant ESCC cell line Eca-109/5-FU, which was prepared by the stepwise exposure to increasing 5-FU concentrations. MTT assay and nude mouse xenograft models were used to test the drug resistance and proliferation of Eca-109 and Eca-109/5-FU cells in vitro and in vivo. Apoptosis and cell cycle distribution were determined using flow cytometry. Drug resistance-related proteins were detected by western blotting. Metabolomic profiles were obtained from nuclear magnetic resonance (NMR) tests. In regards to Eca-109/5-FU, the decreased susceptibility to 5-FU was determined in vitro and in vivo with slower rate of proliferation. Drug resistance-related proteins (multidrug resistance-associated protein 1 and ATP-binding cassette superfamily G member 2), epithelial-to-mesenchymal transition (EMT)-related proteins (E-cadherin and vimentin) and cancer stem cell-related proteins (prominin-1 and hyaluronate receptor) exhibited significant differences between the two cell lines. The 5-FU-resistant cell line Eca-109/5-FU achieved the ability to tolerate 5-FU, which may depend on significant drug resistance-related characteristics, such as EMT and cancer stem cell-like properties. The metabolism of Eca-109/5-FU was altered, and more than 15 metabolites was found to contribute to the difference in the metabolite profile, such as lactate, glutamate, taurine, glutamine, proline, aspartate, methanol, cystine, glycine and uracil. Our results identified that the resistant cell line Eca-109/5-FU showed quite different characteristics compared with the parental Eca-109 cells. The Eca-109/5-FU cell line provides an experimental model for further steps to select chemotherapeutic sensitizers.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Rustgi AK and El-Serag HB: Esophageal carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
3	Stein HJ, Sendler A, Fink U and Siewert JR: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 80:659–686. 2000. View Article : Google Scholar : PubMed/NCBI
4	Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
5	Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet. 24:236–244. 2000. View Article : Google Scholar : PubMed/NCBI
6	Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, et al: NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw. 14:715–724. 2016.PubMed/NCBI
7	Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, Koizumi K, Tsujimoto H and Fukushima M: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 87:212–220. 1996. View Article : Google Scholar : PubMed/NCBI
8	Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, et al: Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Am J Cancer Res. 5:2431–2440. 2015.PubMed/NCBI
9	Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M and Weber G: Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Anticancer Res. 17:2353–2356. 1997.PubMed/NCBI
10	Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, Takechi T, Yamamoto M and Hayashi K: Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 17:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
11	Tang B, Zhang Y, Liang R, Gao Z, Sun D and Wang L: RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncol Rep. 29:1037–1042. 2013.PubMed/NCBI
12	Cai B, Miao Y and Liu Y, Xu X, Guan S, Wu J and Liu Y: Nuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: A human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysis. PLoS One. 8:e696112013. View Article : Google Scholar : PubMed/NCBI
13	Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
14	Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
15	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
16	Elliott BE, Hung WL, Boag AH and Tuck AB: The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 80:91–102. 2002. View Article : Google Scholar : PubMed/NCBI
17	Elshamy WM and Duhé RJ: Overview: Cellular plasticity, cancer stem cells and metastasis. Cancer Lett. 341:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
18	He K, Xu T and Goldkorn A: Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 10:938–948. 2011. View Article : Google Scholar : PubMed/NCBI
19	Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E and Kovacs K: Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol. 24:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF and Cheng XD: 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 11:284–294. 2015. View Article : Google Scholar : PubMed/NCBI
21	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
22	Chen S, Song X, Chen Z, Li X, Li M, Liu H and Li J: CD133 expression and the prognosis of colorectal cancer: A systematic review and meta-analysis. PLoS One. 8:e563802013. View Article : Google Scholar : PubMed/NCBI
23	Toden S, Okugawa Y, Jascur T, Wodarz D, Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A: Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367. 2015. View Article : Google Scholar : PubMed/NCBI
24	Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
25	Harada K, Ferdous T and Ueyama Y: Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol. 44:1302–1308. 2014.PubMed/NCBI
26	Tanaka T, Bai T and Toujima S: Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. Int J Oncol. 37:731–736. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ohashi S, Kikuchi O, Tsurumaki M, Nakai Y, Kasai H, Horimatsu T, Miyamoto S, Shimizu A, Chiba T and Muto M: Preclinical validation of talaporfin sodium-mediated photodynamic therapy for esophageal squamous cell carcinoma. PLoS One. 9:e1031262014. View Article : Google Scholar : PubMed/NCBI
28	Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, et al: Competitive binding between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and thymidylate synthase expression to promote esophageal cancer chemoresistance. Clin Cancer Res. 22:1243–1255. 2016. View Article : Google Scholar : PubMed/NCBI
29	Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, He QY and Cheung AL: Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance - implications for IGF-II and IGF-IR-targeted therapy. Clin Cancer Res. 20:2651–2662. 2014. View Article : Google Scholar : PubMed/NCBI
30	Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, Van der Hoek M, Haier J and Hussey DJ: MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol. 20:14904–14912. 2014. View Article : Google Scholar : PubMed/NCBI
31	Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J and Hussey DJ: Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 15:429–438. 2011. View Article : Google Scholar : PubMed/NCBI
32	Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q and Chen KN: Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget. 7:4531–4541. 2016.PubMed/NCBI
33	Sasada S, Miyata Y, Tsutani Y, Tsuyama N, Masujima T, Hihara J and Okada M: Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. Oncol Rep. 29:925–931. 2013.PubMed/NCBI
34	Weljie AM, Newton J, Mercier P, Carlson E and Slupsky CM: Targeted profiling: Quantitative analysis of 1H NMR metabolomics data. Anal Chem. 78:4430–4442. 2006. View Article : Google Scholar : PubMed/NCBI
35	Ouattara DA, Prot JM, Bunescu A, Dumas ME, Elena-Herrmann B, Leclerc E and Brochot C: Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells. Mol Biosyst. 8:1908–1920. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ma Q, Jin B, Zhang Y, Shi Y, Zhang C, Luo D, Wang P, Duan C, Song H, Li X, et al: Secreted recombinant human IL-24 protein inhibits the proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro and in vivo. Oncol Rep. 35:2681–2690. 2016.PubMed/NCBI
37	Wang TH, Wan JY, Gong X, Li HZ and Cheng Y: Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncol Rep. 28:1681–1686. 2012.PubMed/NCBI
38	Moghanibashi M, Jazii FR, Soheili ZS, Zare M, Karkhane A, Parivar K and Mohamadynejad P: Proteomics of a new esophageal cancer cell line established from Persian patient. Gene. 500:124–133. 2012. View Article : Google Scholar : PubMed/NCBI
39	Baguley BC: Multidrug resistance in cancer. Methods Mol Biol. 596:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
40	Wang C, Guo LB, Ma JY, Li YM and Liu HM: Establishment and characterization of a paclitaxel-resistant human esophageal carcinoma cell line. Int J Oncol. 43:1607–1617. 2013.PubMed/NCBI
41	Dinicola S, Pasqualato A, Proietti S, Masiello MG, Palombo A, Coluccia P, Canipari R, Catizone A, Ricci G, Harrath AH, et al: Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by γ-secretase inhibition. Life Sci. 145:174–183. 2016. View Article : Google Scholar : PubMed/NCBI
42	Yan XD, Li M, Yuan Y, Mao N and Pan LY: Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep. 17:1163–1169. 2007.PubMed/NCBI
43	Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar : PubMed/NCBI
44	Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, et al: 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. 6:41706–41721. 2015.PubMed/NCBI
45	Kim NH, Kim SN, Oh JS, Lee S and Kim YK: Anti-mitotic potential of 7-diethylamino-3(2′-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU. Biochem Biophys Res Commun. 418:616–621. 2012. View Article : Google Scholar : PubMed/NCBI
46	Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H, et al: Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol. 40:1005–1010. 2012.PubMed/NCBI
47	Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K and Hofler H: High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol. 102:503–508. 2010. View Article : Google Scholar : PubMed/NCBI
48	Takebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T and Aikou T: The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer. 82:661–666. 1998. View Article : Google Scholar : PubMed/NCBI
49	Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Shin MG and Kim HJ: OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib. Chonnam Med J. 50:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
50	Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP and Legrand O: MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 11:7764–7772. 2005. View Article : Google Scholar : PubMed/NCBI
51	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
52	Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH and Lee OK: CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 40:61–71. 2013. View Article : Google Scholar : PubMed/NCBI
53	Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
54	Najafzadeh N, Mazani M, Abbasi A, Farassati F and Amani M: Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44⁺ cancer stem cells. Biomed Pharmacother. 74:243–251. 2015. View Article : Google Scholar : PubMed/NCBI
55	Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley JD: A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis. 28:137–155. 2011. View Article : Google Scholar : PubMed/NCBI
56	Cioce M, Valerio M, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Manetti C, Muti P, Strano S, et al: Metformin-induced metabolic reprogramming of chemoresistant ALDH^bright breast cancer cells. Oncotarget. 5:4129–4143. 2014. View Article : Google Scholar : PubMed/NCBI
57	Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H and Tsuchihara K: Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem. 289:20813–20823. 2014. View Article : Google Scholar : PubMed/NCBI
58	Xie C, Jin J, Bao X, Zhan WH, Han TY, Gan M, Zhang C and Wang J: Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget. 7:610–621. 2016.PubMed/NCBI
59	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
60	Qian JQ, Sun P, Pan ZY and Fang ZZ: Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines. Int J Clin Exp Pathol. 8:11934–11944. 2015.PubMed/NCBI
61	Wang PP, Xu DJ, Huang C, Wang WP and Xu WK: Astragaloside IV reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines. Mol Med Rep. 9:2131–2137. 2014.PubMed/NCBI
62	Li Q, Wang X, Shen A, Zhang Y, Chen Y, Sferra TJ, Lin J and Peng J: Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2. Exp Ther Med. 10:1845–1850. 2015.PubMed/NCBI